CommercialCoverageHigh impact
[Georgia] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines
Anthem BCBS·GA · Vascular Surgery, Cardiology, Oncology +3 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 12, 2026
Summary
Carelon Medical Benefits Management updated clinical appropriateness guidelines effective November 15, 2026, with major changes to vascular procedures (adding new ablation modalities, revising criteria for embolization), PFO closure (age-based restrictions), and genetic/molecular testing for cancer (expanding indications for liquid biopsy, somatic tumor testing, and tissue-based molecular profiling across multiple cancer types). Billing teams must review affected procedure approvals and update documentation requirements for cancer-related genetic testing.
Action Required
By November 15, 2026: (1) Billing and authorization teams must review and update prior authorization workflows for vascular procedures including endovascular revascularization (inframalleolar angioplasty), varicose vein treatments (thermal/non-thermal ablation, cyanoacrylate ablation for perforators), vascular embolization (liver malignancy with DEB-TACE, pelvic venous disorder, portal vein embolization, varicocele), and PFO closure (restrict to age ≤60 except with documented high RoPE score). (2) Providers must update cancer genetic testing documentation requirements to reflect expanded indications for molecular profile testing in breast cancer (stages IIB-IIIC), prostate cancer (all metastatic presentations, not limited to mCSPC), colorectal cancer (PIK3CA and KRAS G12C testing), ovarian cancer (maintenance therapy indications), and thyroid cancer (locoregional, recurrent, progressive presentations). (3) Update billing system guidance to exclude non-medically necessary services: PFO closure >age 60, genicular artery embolization (non-universal scenarios), isolated labial/lower extremity varicose veins without pelvic symptoms, ctHPV DNA in oropharyngeal carcinoma, WES/WGS/WTA analysis, and liquid biopsy screening (CancerGuard). (4) Coding and authorization staff must verify that reflex tissue biopsy after uninformative liquid biopsy is pre-approved. Claims without updated authorization protocols or failing to comply with new clinical criteria will be denied.